Publications by authors named "J Sieper"
Background: The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR) were evaluated through 1 year in the SELECT-AXIS 2 study. Here, we assess 2-year efficacy, safety, and imaging outcomes in SELECT-AXIS 2.
Methods: Patients who received continuous upadacitinib, and those who switched from placebo to upadacitinib at week 14, could enter the open-label extension (OLE).
The city and casino of Wiesbaden, capital of the German state Hessen, have endowed the Carol Nachman Prize to promote research work in the field of rheumatology since 1972. The prize, endowed with 37,500 €, is the second highest medical award in Germany and serves to promote clinical, therapeutic, and experimental research work in the field of rheumatology. In June 2022, the 50-year anniversary was celebrated.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to identify lectin pathway proteins (LPPs) as potential biomarkers for diagnosing axial spondyloarthritis (axSpA) in patients with either newly diagnosed axSpA or chronic low back pain (cLBP).
- Serum samples from 515 participants were analyzed, revealing significant differences in levels of certain proteins between axSpA patients and those with cLBP, particularly showing higher L-ficolin, MASP-2, and C3dg in axSpA patients.
- The combination of HLA-B27 with specific LPP measurements enhanced the diagnostic specificity for axSpA, but this came at the cost of sensitivity; C3dg and MASP-3 were highlighted as important markers
Objective: To assess the association of body composition, evaluated by bioimpedance analysis (BIA), with disease activity, physical function, and mobility in patients with axSpA undergoing bDMARD treatment for one year.
Methods: Patients with AS (radiographic axSpA) were enrolled in an extension of the German Spondyloarthritis Inception Cohort (GESPIC). Patients were required to be candidates for bDMARD therapy at baseline presenting high disease activity despite previous treatment with nonsteroidal anti-inflammatory drugs.